PIRCHE AG
Desconocido
ULISES: Immunological incompatibility as a basis for cancer curing and vaccination
PIRCHE AG
participó en un
H2020:
H2020-FETOPEN-2018-2020
In the ULISES project, we aim at developing an immunologic-based treatment strategy where cancer cells are reprogrammed to become visible to...
2020-06-18 - 2024-06-30 | Financiado
2020-06-18 - 2024-06-30 | Financiado
* No se disponen de datos de la empresa actual.